Gould, Janet <br/><br/>
Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation.  [electronic resource] 

 -  Regulatory toxicology and pharmacology : RTP  Aug 2016 
 - S79-93 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1096-0295 
<br/><br/><label>Standard No.: </label>10.1016/j.yrtph.2016.05.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Dose-Response Relationship, Drug<br/>Drug Contamination--prevention & control<br/>Drug Hypersensitivity--immunology<br/>Drug Industry--legislation & jurisprudence<br/>Drug-Related Side Effects and Adverse Reactions--immunology<br/>Guidelines as Topic<br/>Health Policy<br/>Humans<br/>Mutagenicity Tests<br/>No-Observed-Adverse-Effect Level<br/>Occupational Exposure--adverse effects<br/>Occupational Health--legislation & jurisprudence<br/>Pharmaceutical Preparations--classification<br/>Pharmacokinetics<br/>Policy Making<br/>Proteins--adverse effects<br/>Risk Assessment<br/>Toxicity Tests--methods<br/>Toxicokinetics